Ezaki K, Okabe K, Domyo M, Abe K, Kubokawa C, Ogawa M
Gan. 1983 Oct;74(5):723-9.
An ovarian cancer patient was treated with human fibroblast interferon (HFIF) given daily by iv infusion, and the lymphocyte natural killer (NK) activity against K562 and the cytotoxicity against autologous tumor cells under various experimental conditions were investigated. After HFIF treatment, NK activity against K562 increased significantly, whereas the autologous tumor cell kill by lymphocytes was not increased with target tumor cells that were fresh, frozen then thawed, or frozen, thawed and cultured for 4 to 5 days before use. In vitro HFIF-stimulated lymphocytes also did not enhance cytotoxicity against the various autologous tumor cells. However, lymphocytes from allogeneic healthy persons did show enhanced cytotoxicity against cultured tumor cells of this patient after cultivation with HFIF, but had no significant effect against frozen tumor cells. Mixed lymphocyte-tumor cell reaction (MLTR) and MLTR-induced lymphocyte cytotoxicity against autologous tumor cells were not enhanced by HFIF. Thus, tumor-specific immune reactions directed toward autologous tumor cells were not enhanced by HFIF treatment under the conditions tested in this study.
一名卵巢癌患者接受了每天静脉输注人成纤维细胞干扰素（HFIF）的治疗，并研究了在各种实验条件下淋巴细胞对K562的自然杀伤（NK）活性以及对自体肿瘤细胞的细胞毒性。HFIF治疗后，对K562的NK活性显著增加，而对于新鲜的、冷冻后解冻的或冷冻、解冻并培养4至5天再使用的靶肿瘤细胞，淋巴细胞对自体肿瘤细胞的杀伤并未增加。体外经HFIF刺激的淋巴细胞对各种自体肿瘤细胞的细胞毒性也未增强。然而，来自同种异体健康人的淋巴细胞在用HFIF培养后，对该患者的培养肿瘤细胞确实显示出增强的细胞毒性，但对冷冻肿瘤细胞没有显著影响。混合淋巴细胞 - 肿瘤细胞反应（MLTR）以及MLTR诱导的淋巴细胞对自体肿瘤细胞的细胞毒性并未因HFIF而增强。因此，在本研究测试的条件下，HFIF治疗并未增强针对自体肿瘤细胞的肿瘤特异性免疫反应。
